deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT01460134

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors

Sponsor: Celldex Therapeutics

Conditions Any T-cell Malignancy Burkett's Lymphoma CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma Chronic Lymphocytic Leukemia Colorectal Adenocarcinoma, Non-small Cell Lung Cancer) Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer Mantle Cell Lymphoma Marginal Zone B Cell Lymphoma) Primary Lymphoma of the Central Nervous System Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma
Interventions CDX-1127
Updated 7 times since 2017 Last updated: Jan 29, 2018 Started: Oct 31, 2011 Primary completion: Dec 31, 2015 Completion: Oct 16, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Any T-cell Malignancy and Burkett's Lymphoma, this trial is completed. The trial is conducted by Celldex Therapeutics and has accumulated 7 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshotActive Not Recruiting~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2018 — Jun 2018 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

  1. Feb 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celldex Therapeutics
Data source: Celldex Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations